HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 5 (2008), Issue 5 (May)

1. Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV.
   Science, 320(5876): 649-52. [Abstract] [Full-text]
2. Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction.
   PLoS Pathog, 4(5): e1000057. [Abstract] [Full-text]
3. Perioperative guidelines for elective surgery in the human immunodeficiency virus-positive patient.
   Plast Reconstr Surg, 121(5): 1831-40. [Abstract] [Full-text]
4. Inhibition of V3-specific cleavage of recombinant HIV-1 gp120 produced in Chinese hamster ovary cells.
   Protein Expr Purif, 59(2): 223-31. [Abstract] [Full-text]
5. Mutations generated in human immunodeficiency virus type 1 long terminal repeat during vertical transmission correlate with viral gene expression.
   Virology, 375(1): 170-81. [Abstract] [Full-text]
6. APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells.
   Virology, 375(1): 1-12. [Abstract] [Full-text]
7. HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein.
   Virology, 375(1): 148-58. [Abstract] [Full-text]
8. Ezrin, Radixin, and Moesin (ERM) proteins function as pleiotropic regulators of human immunodeficiency virus type 1 infection.
   Virology, 375(1): 130-40. [Abstract] [Full-text]
9. Activation of the glucocorticoid receptor releases unstimulated PBMCs from an early block in HIV-1 replication.
   Virology, 375(1): 73-84. [Abstract] [Full-text]
10. The requirement of the DEAD-box protein DDX24 for the packaging of human immunodeficiency virus type 1 RNA.
    Virology, 375(1): 253-64. [Abstract] [Full-text]
11. Selective targeting of ITK blocks multiple steps of HIV replication.
    Proc Natl Acad Sci U S A, 105(18): 6684-9. [Abstract] [Full-text]
12. HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.
    J Am Chem Soc, 130(19): 6099-113. [Abstract] [Full-text]
13. Structural probing of the HIV-1 polypurine tract RNA:DNA hybrid using classic nucleic acid ligands.
    Nucleic Acids Res, 36(8): 2799-810. [Abstract] [Full-text]
14. Assessing proficiency of interpretation of rapid human immunodeficiency virus assays in nonlaboratory settings: ensuring quality of testing.
    J Clin Microbiol, 46(5): 1692-7. [Abstract] [Full-text]
15. Optimizing screening for acute human immunodeficiency virus infection with pooled nucleic acid amplification tests.
    J Clin Microbiol, 46(5): 1785-92. [Abstract] [Full-text]
16. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States.
    J Clin Microbiol, 46(5): 1588-95. [Abstract] [Full-text]
17. Use of antidepressants and risk of cancer in individuals infected with HIV.
    J Clin Oncol, 26(14): 2305-10. [Abstract] [Full-text]
18. Investigating human immunodeficiency virus-1 proteinase specificity at positions P4 to P2 using a bacterial screening system.
    Anal Biochem, 377(2): 162-9. [Abstract] [Full-text]
19. Recombination increases human immunodeficiency virus fitness, but not necessarily diversity.
    J Gen Virol, 89: 1467-77. [Abstract] [Full-text]
20. Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women.
    J Gen Virol, 89: 1380-9. [Abstract] [Full-text]
21. Class-sparing regimens for initial treatment of HIV-1 infection.
    N Engl J Med, 358(20): 2095-106. [Abstract] [Full-text]
22. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1.
    J Virol, 82(11): 5548-61. [Abstract] [Full-text]
23. Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid.
    J Virol, 82(11): 5594-605. [Abstract] [Full-text]
24. A fusion inhibitor prevents spread of immunodeficiency viruses, but not activation of virus-specific T cells, by dendritic cells.
    J Virol, 82(11): 5329-39. [Abstract] [Full-text]
25. Importance of the membrane-perturbing properties of the membrane-proximal external region of human immunodeficiency virus type 1 gp41 to viral fusion.
    J Virol, 82(11): 5118-26. [Abstract] [Full-text]
26. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein.
    J Virol, 82(11): 5584-93. [Abstract] [Full-text]
27. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation.
    J Virol, 82(11): 5643-9. [Abstract] [Full-text]
28. Increased in vivo activation of microglia and astrocytes in the brains of mice transgenic for an infectious R5 human immunodeficiency virus type 1 provirus and for CD4-specific expression of human cyclin T1 in response to stimulation by lipopolysaccharides.
    J Virol, 82(11): 5562-72. [Abstract] [Full-text]
29. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.
    J Virol, 82(11): 5398-407. [Abstract] [Full-text]
30. Role of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein in cell-cell fusion and virus infection.
    J Virol, 82(11): 5417-28. [Abstract] [Full-text]
31. Maraviroc: integration of a new antiretroviral drug class into clinical practice.
    J Antimicrob Chemother, 61(6): 1187-90. [Abstract] [Full-text]
32. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
    J Antimicrob Chemother, 61(6): 1362-8. [Abstract] [Full-text]
33. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
    J Antimicrob Chemother, 61(6): 1201-4. [Abstract] [Full-text]
34. HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C.
    J Antimicrob Chemother, 61(6): 1217-20. [Abstract] [Full-text]
35. HIV-1 at 25.
    Cell, 133(4): 561-5. [Abstract] [Full-text]
36. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.
    Clin Pharmacol Ther, 83(6): 867-72. [Abstract] [Full-text]
37. Fertility services for human immunodeficiency virus-positive patients: provider policy, practice, and perspectives.
    Fertil Steril, 89(5): 1154-8. [Abstract] [Full-text]
38. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.
    Virology, 375(2): 529-38. [Abstract] [Full-text]
39. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination.
    Virology, 375(2): 315-20. [Abstract] [Full-text]
40. TRIM5alpha-independent anti-human immunodeficiency virus type 1 activity mediated by cyclophilin A in Old World monkey cells.
    Virology, 375(2): 514-20. [Abstract] [Full-text]
41. Systemic and mucosal immunological responses during repeated mucosal SHIV(162P3) challenges prior to and following infection in pigtailed macaques.
    Virology, 375(2): 492-503. [Abstract] [Full-text]
42. Functional complementation of nucleocapsid and late domain PTAP mutants of human immunodeficiency virus type 1 during replication.
    Virology, 375(2): 539-49. [Abstract] [Full-text]
43. Mapping of nucleocapsid residues important for HIV-1 genomic RNA dimerization and packaging.
    Virology, 375(2): 592-610. [Abstract] [Full-text]
44. Productive infection of human immunodeficiency virus type 1 in dendritic cells requires fusion-mediated viral entry.
    Virology, 375(2): 442-51. [Abstract] [Full-text]
45. HIV-1 latency in actively dividing human T cell lines.
    Retrovirology, 5: 37. [Abstract] [Full-text]
46. Immune cellular parameters of leprosy and human immunodeficiency virus-1 co-infected subjects.
    Immunology, 124(2): 206-14. [Abstract] [Full-text]
47. Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron.
    Nucleic Acids Res, 36(9): 2811-24. [Abstract] [Full-text]
48. Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation.
    RNA, 14(6): 1228-36. [Abstract] [Full-text]
49. Selective killing of HIV-1-positive macrophages and T cells by the Rev-dependent lentivirus carrying anthrolysin O from Bacillus anthracis.
    Retrovirology, 5: 36. [Abstract] [Full-text]
50. A lentiviral vector with novel multiple cloning sites: stable transgene expression in vitro and in vivo.
    Biochem Biophys Res Commun, 371(3): 546-50. [Abstract] [Full-text]
51. Setting the stage: host invasion by HIV.
    Nat Rev Immunol, 8(6): 447-57. [Abstract] [Full-text]
52. Human immunodeficiency virus (HIV-1) infection selectively downregulates PD-1 expression in infected cells and protects the cells from early apoptosis in vitro and in vivo.
    Virology, 376(1): 140-53. [Abstract] [Full-text]
53. Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells.
    Virology, 376(1): 101-11. [Abstract] [Full-text]
54. Susceptibility to virus-cell fusion at the plasma membrane is reduced through expression of HIV gp41 cytoplasmic domains.
    Virology, 376(1): 69-78. [Abstract] [Full-text]
55. Creation of a bi-directional protein transduction system for suppression of HIV-1 expression by p27SJ.
    Antiviral Res, 79(2): 136-41. [Abstract] [Full-text]
56. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.
    Proc Natl Acad Sci U S A, 105(21): 7552-7. [Abstract] [Full-text]
57. Sexually transmitted infections knowledge and its impact in the practice of risky sexual behaviours and HIV serostatus: results from rural Kilimanjaro, Tanzania.
    Sex Transm Infect, 84(3): 224-6. [Abstract] [Full-text]
58. Longitudinal effect following initiation of highly active antiretroviral therapy on plasma and cervico-vaginal HIV-1 RNA among women in Burkina Faso.
    Sex Transm Infect, 84(3): 167-70. [Abstract] [Full-text]
59. Insights into cellular microRNAs and human immunodeficiency virus type 1 (HIV-1).
    J Cell Physiol, 216(2): 327-31. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.